Stock Report

All about this stock under one free report Last Updated: 08-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Calliditas Therapeutics AB (CALT) Key Ratios

Stock Card factsheet share-fund-plan-icon

$40.00

$0.00 (0.00%)

As on 27-Sep-2024 09:30EDT

Market cap

info icon

$1,097 Mln

Revenue (TTM)

info icon

$1,601 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

103.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 89.45 107.80 39.27 1,160.29 63.22
EBIT 83.22 54.82 -71.35 11.15 -257.81
Net Profit 80.71 48.36 -64.37 -3.84 -263.60
EPS 80.72 48.37 -56.24 16.21 -244.70
Book Value -- -- -78.32 -49.51 -29.22
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -103.47-8,811.48-23.02-31.85-52.55
Net Margin info -----30.00----
Return on equity info -59.02-45.08-217.56-84.68-46.46
Return on Capital info -35.12-30.68---33.19-30.35
Return on Assets info -27.57-24.84-23.00-24.20-24.16
Debt to Equity (x) info ----9.202.920.95

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
-33.19
-30.35
-41.82
-43.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-217.56

Lower than Peers by 195.55

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-217.56
-84.68
-46.46
-45.93
-43.68
Peer Median
-22.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-23.00

Lower than Peers by 10.45

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-23.00
-24.20
-24.16
-34.35
-37.12
Peer Median
-12.55
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-23.02

Higher than Peers by 27.21

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-23.02
-31.85
-52.55
-226.02
-43,732.38
Peer Median
-50.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-30.00

Higher than Peers by 26.79

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-30.00
-38.63
-51.35
-222.17
-49,944.05
Peer Median
-56.78
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

39.27

Higher than Peers by 23.18

Year on year growth in net sales

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
39.27
0.50
2.50
261.41
-1.00
Peer Median
16.10
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-71.35

Lower than Peers by 84.03

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-71.35
8.90
18.60
-35.62
-1,318.15
Peer Median
12.68
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-64.37

Lower than Peers by 72.76

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-64.37
-13.08
19.09
-16.73
-1,239.90
Peer Median
8.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-56.24

Lower than Peers by 87.49

Year on year growth in earnings per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-56.24
0.44
0.20
-0.11
-9.38
Peer Median
31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-78.83

Lower than Peers by 80.97

Year on year growth in book value per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-78.83
--
--
--
--
Peer Median
2.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

9.20

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
9.20
2.92
0.95
0.21
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
0.04
0.01
0.05
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.69

Lower than Peers by 1.03

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
2.69
3.13
4.34
7.48
9.82
Peer Median
3.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.59

Lower than Peers by 1.08

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
2.59
3.08
4.33
7.47
9.82
Peer Median
3.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-3.07

Lower than Peers by 2.73

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
-3.07
-5.25
-33.69
-72.93
-972.57
Peer Median
-0.34
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

13.90

Lower than Peers by 9.42

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
13.90
15.59
10.09
24.58
2,030.43
Peer Median
23.32
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.77

Higher than Peers by 0.51

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
0.77
0.63
0.47
0.15
0.00
Peer Median
0.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
40.73
31.25
59.02
13,442.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
57.06
54.50
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
618.49
2,743.70
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Calliditas Therapeutics AB (CALT)
--
-520.70
-2,657.96
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...